New Zealand markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
130.94-5.59 (-4.09%)
At close: 04:00PM EST
130.00 -0.94 (-0.72%)
After hours: 04:52PM EST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2020
31/12/2019
31/12/2018
Total revenue
749,314
492,853
219,750
74,908
Cost of revenue
125,504
78,052
25,062
1,802
Gross profit
623,810
414,801
194,688
73,106
Operating expenses
Research development
731,575
654,819
655,114
505,420
Selling general and administrative
600,548
588,420
479,005
382,359
Total operating expenses
1,332,123
1,243,239
1,134,119
887,779
Operating income or loss
-708,313
-828,438
-939,431
-814,673
Interest expense
134,722
84,496
-
-
Total other income/expenses net
5,418
45,525
20,730
24,737
Income before tax
-835,441
-855,600
-885,253
-760,674
Income tax expense
2,463
2,681
863
823
Income from continuing operations
-837,904
-858,281
-886,116
-761,497
Net income
-837,904
-858,281
-886,116
-761,497
Net income available to common shareholders
-837,904
-858,281
-886,116
-761,497
Basic EPS
-
-7.46
-8.11
-7.57
Diluted EPS
-
-7.46
-8.11
-7.57
Basic average shares
-
114,986
109,264
100,590
Diluted average shares
-
114,986
109,264
100,590
EBITDA
-
-736,332
-922,256
-808,238